Profile picture of Amicus Therapeutics

Amicus Therapeutics

Cranbury, NJ
2 staff members
2.5 277 Reviews
Company Profile

Amicus Therapeutics develops drugs that treat rare genetic diseases known as lysosomal storage disorders. Unlike other treatments which replace defective enzymes, Amicus uses small molecule pharmacological "chaperones" which bind to a patient's own defective proteins and restore their functions. Its lead drug candidate, Amigal, is aimed at aiding patients with Fabry disease. Another candidate, Plicera, is in development to treat Gaucher disease, while a third candidate, AT2220 is targeting Pompe disease. The company is also researching treatments for neurodegenerative diseases including Alzheimer's and Parkinson's.

Company size

51 to 200

Type

Company - Public (FOLD)

Revenue

$1 to $5 million (USD) per year

Industry

Biotech & Pharmaceuticals

Competitors

Actelion Group

Founded

2005

Staff Members
avatar
CEO
1.0
Worked since Monday, Jun 17 2024
People Also Viewed